Cargando…
Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities
Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults. Currently, the standard treatment of glioblastoma includes surgery, radiotherapy, and chemotherapy. Despite aggressive treatment, the median survival is only 15 months. GBM progression and therapeutic resistance are t...
Autores principales: | Wang, Guoqing, Zhong, Kunhong, Wang, Zeng, Zhang, Zongliang, Tang, Xin, Tong, Aiping, Zhou, Liangxue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363573/ https://www.ncbi.nlm.nih.gov/pubmed/35967394 http://dx.doi.org/10.3389/fimmu.2022.964898 |
Ejemplares similares
-
Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma
por: Li, Gaowei, et al.
Publicado: (2021) -
Immunotherapy of glioblastoma: Recent advances and future prospects
por: Yuan, Boyang, et al.
Publicado: (2022) -
B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma
por: Tang, Xin, et al.
Publicado: (2019) -
Loss of furin site enhances SARS-CoV-2 spike protein pseudovirus infection
por: Wang, Zeng, et al.
Publicado: (2023) -
Genome-scale CRISPR–Cas9 screen reveals novel regulators of B7-H3 in tumor cells
por: Zhao, Shasha, et al.
Publicado: (2022)